Mihaly M.
- Country
- Hungary
- Department
- NA
Research Overview
- A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
- Phase 2 Open-Label Study of Venetoclax, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
- Efficacy and Safety of Birtamimab with Standard Care versus Placebo in Mayo Stage IV Light Chain Amyloidosis: A Phase 3 Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 192 of 413 partner sites.
Specializations
Multiple Myeloma Research
Specializes in investigating novel therapeutic approaches for multiple myeloma, with particular emphasis on both newly diagnosed cases and relapsed/refractory multiple myeloma. Focuses on evaluating innovative treatment combinations and emerging therapies.
- Novel drug combinations
- Treatment resistance studies
- Early intervention strategies
Lymphoid Malignancies
Conducts research in various lymphoid disorders including chronic lymphocytic leukemia, follicular lymphoma, and Hodgkin lymphoma. Investigates targeted therapies and immunotherapy approaches.
- Antibody-based treatments
- Combination therapies
- Immunological interventions
Rare Blood Disorders
Investigates treatments for rare hematological conditions including AL amyloidosis, myelofibrosis, and myelodysplastic syndromes. Focuses on developing therapeutic solutions for challenging blood disorders.
- Novel therapeutic agents
- Disease-modifying approaches
- Treatment of refractory conditions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.